EGFR and lung adenocarcinoma: EGFR-TKI-sensitive (PC9-6M) lung adenocarcinoma cells were treated with 0.1 μM concentration of Gefitinib or Erlotinib alone compared or in combination with TKIs- with increasing concentration of BR2-2xPPD peptides (0–2.5 μM) for 72 h.